Kazia Therapeutics Begins Dosing in Breast Cancer Trial with Promising AI-Enabled Therapy

Kazia Therapeutics (NASDAQ: KZIA) has announced the first patient has been dosed in its new Phase 1b trial evaluating paxalisib in advanced breast cancer. The trial is designed to explore the potential of paxalisib, Kazia’s dual PI3K/mTOR inhibitor, in combination with immunotherapy and chemotherapy, targeting patients with advanced or metastatic disease.

“This marks an important milestone in the evolution of paxalisib beyond brain cancer and into broader solid tumor applications,” said Dr. John Friend, CEO of Kazia. He noted the combinations being studied aim to target tumor metabolism, DNA repair, and immune evasion for better patient outcomes.

The trial includes two treatment arms: one combining paxalisib with olaparib, a PARP inhibitor, and the other with pembrolizumab and standard chemotherapy. The study will assess safety, immune function, and early signs of clinical benefit, including tumor response.

The company sees this trial as a key step in expanding paxalisib’s utility outside the central nervous system. For patients, it represents a new opportunity in an area of high unmet need, particularly in triple-negative breast cancer (TNBC), where treatment options are limited.

Analyst Commentary

Maxim Group analysts Naz Rahman and Dr. Jason McCarthy reiterated a Buy rating and $15 price target, noting that while glioblastoma (GBM) remains Kazia’s lead indication, this breast cancer trial could be a “meaningful inflection point” for the stock.

They highlighted that the trial is being investigator-funded and does not require capital from Kazia, while offering potential upside by providing data on safety, immune re-sensitization, and efficacy beyond brain cancers.

“We believe investors are overlooking this study,” the analysts wrote. “Early results expected in the first half of 2026 could validate paxalisib’s mechanism and broaden its value proposition.”

The team pointed to preclinical evidence showing paxalisib enhances the effect of immunotherapies in TNBC models and cited additional data presented at the San Antonio Breast Cancer Symposium supporting its use in breast cancer with brain metastases.

Maxim’s model applies a 50% risk adjustment to paxalisib sales, a 30% discount rate, and currently values the company at $15 per share.